Kyverna Therapeutics, Inc.
KYTX
$7.18
$0.629.45%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -160.99M | -158.70M | -145.42M | -127.48M | -110.66M |
| Total Depreciation and Amortization | 1.99M | 2.14M | 2.15M | 2.13M | 2.03M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.53M | 3.82M | 2.12M | 3.24M | 4.04M |
| Change in Net Operating Assets | -2.78M | 11.33M | 7.51M | 7.86M | 8.83M |
| Cash from Operations | -157.25M | -141.41M | -133.64M | -114.25M | -95.75M |
| Capital Expenditure | -538.00K | -638.00K | -1.66M | -2.21M | -2.01M |
| Sale of Property, Plant, and Equipment | 70.00K | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 86.99M | 65.28M | -30.78M | -158.70M | -156.44M |
| Cash from Investing | 86.52M | 64.64M | -32.45M | -160.90M | -158.44M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -970.00K | -1.09M | -1.07M | -956.00K | -928.00K |
| Issuance of Common Stock | 1.69M | 125.00K | 198.00K | 341.43M | 341.67M |
| Repurchase of Common Stock | -94.00K | -51.00K | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | 0.00 |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -412.00K | -412.00K | -482.00K | -3.36M | -4.85M |
| Cash from Financing | 210.00K | -1.43M | -1.35M | 337.11M | 335.89M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -70.51M | -78.20M | -167.44M | 61.96M | 81.70M |